Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:22 pm Sale |
2024-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Citadel Advisors LLC | 21,083 0.000% |
-4,265,844 (-99.51%) |
Filing History |
| 2024-12-16 9:02 pm Unchanged |
2024-12-12 | 13D | Lyra Therapeutics, Inc. LYRA |
PERCEPTIVE ADVISORS LLC | 12,757,562 19.500% |
0 (Unchanged) |
Filing History |
| 2024-11-14 7:48 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Point72 Asset Management, L.P. | 0 0.000% |
-3,030,283 (Position Closed) |
Filing History |
| 2024-11-14 5:49 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 1,204,094 1.800% |
-4,349,458 (-78.32%) |
Filing History |
| 2024-11-14 5:48 pm Purchase |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Samsara BioCapital, L.P. | 3,281,766 4.980% |
501,505 (+18.04%) |
Filing History |
| 2024-11-14 4:53 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Nantahala Capital Management, LLC | 702,106 1.061% |
-4,050,218 (-85.23%) |
Filing History |
| 2024-11-14 12:00 pm Sale |
2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA |
Vestal Point Capital, LP | 0 0.000% |
-3,000,000 (Position Closed) |
Filing History |
| 2024-08-15 6:31 pm Sale |
2024-08-14 | 13D | Lyra Therapeutics, Inc. LYRA |
PERCEPTIVE ADVISORS LLC | 12,757,562 19.500% |
-1 (-0.00%) |
Filing History |
| 2024-02-15 09:18 am Sale |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Pura Vida Investments, LLC | 1,613,844 3.060% |
-543,454 (-25.19%) |
Filing History |
| 2024-02-14 8:35 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Venrock Healthcare Capital Partners II, L.P. | 5,553,552 9.999% |
2,120,284 (+61.76%) |
Filing History |
| 2024-02-14 6:18 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Citadel Advisors LLC | 4,286,927 7.900% |
1,390,392 (+48.00%) |
Filing History |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Nantahala Capital Management, LLC | 4,752,324 8.900% |
2,531,494 (+113.99%) |
Filing History |
| 2024-02-14 4:29 pm Unchanged |
2024-02-14 | 13D | Lyra Therapeutics, Inc. LYRA |
PERCEPTIVE ADVISORS LLC | 12,757,563 24.300% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:18 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Point72 Asset Management, L.P. | 3,030,283 5.800% |
30,283 (+1.01%) |
Filing History |
| 2024-02-13 4:34 pm Purchase |
2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Vestal Point Capital, LP | 3,000,000 5.700% |
3,000,000 (New Position) |
Filing History |
| 2023-11-16 5:00 pm Purchase |
2023-11-15 | 13G | Lyra Therapeutics, Inc. LYRA |
Point72 Asset Management, L.P. | 3,000,000 5.400% |
3,000,000 (New Position) |
Filing History |
| 2023-08-25 4:15 pm Purchase |
2022-04-12 | 13G | Lyra Therapeutics, Inc. LYRA |
Samsara BioCapital, L.P. | 2,780,261 5.600% |
2,780,261 (New Position) |
Filing History |
| 2023-06-12 5:23 pm Purchase |
2023-05-31 | 13G | Lyra Therapeutics, Inc. LYRA |
Citadel Advisors LLC | 2,896,535 5.900% |
2,896,535 (New Position) |
Filing History |
| 2023-06-09 4:20 pm Purchase |
2023-05-31 | 13D | Lyra Therapeutics, Inc. LYRA |
NBVM GP LLC | 6,031,468 12.200% |
1,812,666 (+42.97%) |
Filing History |
| 2023-06-02 4:16 pm Purchase |
2023-05-31 | 13D | Lyra Therapeutics, Inc. LYRA |
PERCEPTIVE ADVISORS LLC | 12,757,563 25.800% |
3,610,832 (+39.48%) |
Filing History |